NCT02191618

Brief Summary

The study is a prospective, multicenter single-arm cohort. Patients with wide neck bifurcation aneurysms (WNBAs) have few choices for safe and effective endovascular treatment. In this study, all patients with qualifying WNBAs will be treated with the WEB. The primary effectiveness outcome of the study is the likelihood of complete intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2014

Longer than P75 for not_applicable

Geographic Reach
6 countries

32 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 14, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 16, 2014

Completed
16 days until next milestone

Study Start

First participant enrolled

August 1, 2014

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2017

Completed
2.6 years until next milestone

Results Posted

Study results publicly available

April 14, 2020

Completed
3.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2023

Completed
Last Updated

December 27, 2024

Status Verified

April 1, 2020

Enrollment Period

3.1 years

First QC Date

July 14, 2014

Results QC Date

February 18, 2020

Last Update Submit

December 9, 2024

Conditions

Keywords

AneurysmIntracranial AneurysmVascular DiseasesCardiovascular DiseasesIntracranial Arterial DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Outcome Measures

Primary Outcomes (2)

  • The Primary Safety Endpoint Included Any Death or Major Stroke in the First 30 Days and Neurologic Death or Ipsilateral Major Stroke Between Day 31 and Day 365.

    The study's primary safety endpoint was the proportion of subjects with death of any nonaccidental cause or any major stroke (defined as an ischemic or hemorrhagic stroke resulting in an increase of 4 points or more on the National Institutes of Health Stroke Scale (NIHSS)) within the first 30 days after treatment or major ipsilateral stroke or death due to neurologic cause from day 31 to 365 days after treatment.

    12 months

  • Percentage of Subjects With Complete Aneurysm Occlusion Assessed Using the WEB Occlusion Scale (WOS) Without Retreatment, Recurrent Subarachnoid Hemorrhage, Without Significant Parent Artery Stenosis (>50% Stenosis) at One Year After Treatment

    The primary effectiveness endpoint was defined as the percentage of subjects with complete aneurysm occlusion assessed using the WEB Occlusion Scale (WOS) without retreatment, recurrent subarachnoid hemorrhage, without significant parent artery stenosis (\>50% stenosis) at one year after treatment in the mITT population.

    12 months

Study Arms (1)

WEB Aneurysm Embolization Device

OTHER

The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant.

Device: WEB

Interventions

WEBDEVICE

The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.

Also known as: WEB Aneurysm Embolization Device
WEB Aneurysm Embolization Device

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient whose age ≥18 and ≤75 years.
  • Patient must have a single ruptured or unruptured IA (intracranial aneurysm) requiring treatment.
  • Patient must sign and date an IRB/EC-approved written informed consent prior to initiation of any study procedures.

You may not qualify if:

  • Patient has an IA with characteristics unsuitable for endovascular treatment
  • Patient has stroke-in-evolution within the prior 60 days
  • Patient has had an SAH (subarachnoid hemorrhage) from a nonindex IA or any other intracranial hemorrhage within 90 days
  • Patient's index IA was previously treated
  • Patient is pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (32)

Barrow Neurological Institute

Phoenix, Arizona, 85013, United States

Location

Sequent Medical

Aliso Viejo, California, 92565, United States

Location

Radiology Imaging Associates P.C.

Englewood, Colorado, 80112, United States

Location

Lyerly Baptist, Inc

Jacksonville, Florida, 32207, United States

Location

Rush University Medical Center

Chicago, Illinois, 60612, United States

Location

University of Louisville

Louisville, Kentucky, 40202, United States

Location

Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States

Location

Brigham and Women's Hospital

Boston, Massachusetts, 021115, United States

Location

Tufts Medical Center

Boston, Massachusetts, 02111, United States

Location

Abbott Northwestern Hospital

Minneapolis, Minnesota, 55407, United States

Location

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

Albany Medical Center

Albany, New York, 12208, United States

Location

Buffalo General Medical Center

Buffalo, New York, 14203, United States

Location

The Mount Sinai Medical Center

New York, New York, 10029, United States

Location

Stony Brook University

Stony Brook, New York, 11794, United States

Location

Carolina NeuroSurgery & Spine Associates, P.A.

Charlotte, North Carolina, 28204, United States

Location

Riverside Methodist Hospital/ Ohio Health Research Institute

Columbus, Ohio, 43214, United States

Location

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States

Location

Medical University of South Carolina (MUSC)

Charleston, South Carolina, 29425, United States

Location

Ft. Sanders Regional Medical Center

Knoxville, Tennessee, 37916, United States

Location

Methodist University Hospital

Memphis, Tennessee, 38104, United States

Location

Baptist Memorial Hospital

Memphis, Tennessee, 38120, United States

Location

Baylor College of Medicine

Houston, Texas, 77030, United States

Location

University of Texas Health Science Center at Houston

Houston, Texas, 77030, United States

Location

University of Utah Medical Center

Salt Lake City, Utah, 84132, United States

Location

West Virginia University

Morgantown, West Virginia, 26505, United States

Location

Royal University Hospital

Saskatoon, Saskatchewan, S7N 0W8, Canada

Location

Rigshospitalet

Copenhagen, 2100, Denmark

Location

Helios Hospital

Erfurt, 99028, Germany

Location

National Institute of Neurosciences

Budapest, 1145, Hungary

Location

Koru Hospital

Ankara, Turkey (Türkiye)

Location

Marmara University Faculty of Medicine Pendik Training and Research Hospital

Istanbul, Turkey (Türkiye)

Location

Related Publications (2)

  • Arthur AS, Molyneux A, Coon AL, Saatci I, Szikora I, Baltacioglu F, Sultan A, Hoit D, Delgado Almandoz JE, Elijovich L, Cekirge S, Byrne JV, Fiorella D; WEB-IT Study investigators. The safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide-necked bifurcation aneurysms: final 12-month results of the pivotal WEB Intrasaccular Therapy (WEB-IT) Study. J Neurointerv Surg. 2019 Sep;11(9):924-930. doi: 10.1136/neurintsurg-2019-014815. Epub 2019 Apr 16.

  • Fiorella D, Molyneux A, Coon A, Szikora I, Saatci I, Baltacioglu F, Sultan A, Arthur A; WEB-IT Study Investigators. Demographic, procedural and 30-day safety results from the WEB Intra-saccular Therapy Study (WEB-IT). J Neurointerv Surg. 2017 Dec;9(12):1191-1196. doi: 10.1136/neurintsurg-2016-012841. Epub 2017 Jan 17.

MeSH Terms

Conditions

Intracranial AneurysmAneurysmVascular DiseasesCardiovascular DiseasesIntracranial Arterial DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Results Point of Contact

Title
Director, Clinical Operations
Organization
Sequent Medical, Inc

Study Officials

  • Adam Arthur, MD

    Methodist University Hospital, Memphis, TN

    PRINCIPAL INVESTIGATOR
  • David Fiorella, MD

    Stony Brook University, Stony Brook, NY

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 14, 2014

First Posted

July 16, 2014

Study Start

August 1, 2014

Primary Completion

September 1, 2017

Study Completion

June 1, 2023

Last Updated

December 27, 2024

Results First Posted

April 14, 2020

Record last verified: 2020-04

Locations